NEMALIFE INC
Lubbock, TX · Biotech · Private
AI-assisted high-throughput screening platform using C. elegans to identify anti-sarcopenia drug candidates
nemalifeinc.com →- Grants
- $3.2M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 0 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · High-throughput testing of anti-aging and FDA approved drugs in genetically diverse invertebrate Alzheimer's models | $348,285 | |
| Federal grant | Department of Health and Human Services · Phase I · High-throughput testing of anti-aging and FDA approved drugs in genetically diverse invertebrate Alzheimer's models | $348,285 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel technology to assess chronic toxicity in genetically diverse nematode populations | $251,040 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel technology to assess chronic toxicity in genetically diverse nematode populations | $251,040 | |
| Federal grant | Department of Health and Human Services · Phase I · AI-assisted behavioral profiling of an invertebrate model to identify new psychedelic therapeutics for stimulant use disorders | $318,373 | |
| Federal grant | Department of Health and Human Services · Phase I · AI-assisted behavioral profiling of an invertebrate model to identify new psychedelic therapeutics for stimulant use disorders | $318,373 | |
| Federal grant | Department of Health and Human Services · Phase I · High throughput functional screening of anti-sarcopenia therapeutics | $398,019 | |
| Federal grant | Department of Health and Human Services · Phase I · High throughput functional screening of anti-sarcopenia therapeutics | $398,019 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of an AI-assisted therapeutic discovery platform for Alcohol Use Disorders using an invertebrate model | $322,070 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a high throughput in vivo screening platform for identifying novel pro-and postbiotic bacterial strains | $295,780 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2162 | Avanti Biosciences Inc | — | — |
| 2163 | VAXCYTE, INC. | — | — |
| 2164 | Arctus Biosciences | — | — |
| 2165 | NEMALIFE INC | — | — |
| 2166 | PRIME LABS INC | — | — |
| 2167 | Immunovant | — | $450M |
| 2168 | Ocugen | — | $126M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- A Rapid Microfluidic In Vivo Bioassay For Evaluating The Cognitive Health Benefits Of Compoundsapplication
- A Rapid Microfluidic In Vivo Bioassay For Screening Functional Ingredients For Improving Gut Healthapplication
- Rapid Microfluidic In Vivo Bioassay For Evaluating The Cognitive Health Benefits Of Compoundsapplication
- Rapid Microfluidic In Vivo Bioassay For Screening Functional Ingredients For Improving Gut Healthapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.